Revive Therapeutics (TSE:RVV) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Revive Therapeutics has updated stakeholders on the progress of their lateral flow test kit for detecting long COVID, following guidance from the FDA to pursue a De Novo regulatory pathway, which requires a clinical study for potential approval. As there’s no FDA-approved clinical diagnosis for long COVID yet, the company has secured exclusive rights to novel blood biomarkers for the condition, aiming to address a critical need in post-COVID-19 healthcare.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.